Clinical Trial

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

Study acronym: ANIMA - Italy
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on secukinumab, healthcare resource utilization and the economic impact of HS in Italy.
Protocol Amendment History 2 changes
notable Trial sites expanded: 11 -> 16 locations 2026-07-21
notable Trial sites expanded: 8 -> 11 locations 2026-05-23
Trial Details
NCT Number NCT07543419
Lead Sponsor Novartis Pharmaceuticals
Conditions Hidradenitis Suppurativa
Enrollment 250 participants
Start Date 2025-12-17
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20